Reglagene, LLC

TUCSON, AZ · Founded 2018 · CIK 0001747083 · Biotech · Private

Brain-penetrant small molecule therapeutics for neurological diseases

reglagene.com →
Grants
$702K
2 awards
Sector median: 1
Raised
$1.9M
4 Form D · May 2024
29 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$546,413
Federal grantDepartment of Health and Human Services · Phase I · DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer$300,000
Federal grantDepartment of Health and Human Services · Phase I · Glioblastoma multiforme therapy via telomerase reverse transcriptase (hTERT) down-regulation. Molecular chaperones redirect quadruplex folding to reverse the effect of hTERT gene promoter mutations.$401,714
Private capital raisedForm D · SEC$600,000
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$766,655
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1603Acer Therapeutics Inc.—$8.2M
1604CeleCor Therapeutics, Inc.—$3.7M
1605THERALINK TECHNOLOGIES, INC.—$2.6M
1606Reglagene, LLC—$1.9M
1607XenoTherapeutics Corp—$1.3M
1608RIBO-THERAPEUTICS LLC——
1609Yuva Biosciences, Inc.—$1.1M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Richard AustinDirector · Executive Officer
  • Sharon AydDirector
  • David BearssDirector
  • Laurence HurleyDirector
  • Lawrence KinetDirector
  • Ayd SharonDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.